Search results
Showing 31 to 45 of 60 results for ipilimumab
Pembrolizumab with axitinib for untreated advanced renal cell carcinoma (TA650)
Evidence-based recommendations on pembrolizumab (Keytruda) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Avelumab with axitinib for untreated advanced renal cell carcinoma (TA645)
Evidence-based recommendations on avelumab (Bavencio) with axitinib (Inlyta) for untreated advanced renal cell carcinoma in adults.
Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck [ID1355]
Discontinued Reference number: GID-TA10321
Discontinued Reference number: GID-TA10499
Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]
Discontinued Reference number: GID-TA10631
Discontinued Reference number: GID-TA10512
Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]
Discontinued Reference number: GID-TA10585
Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer [ID1228]
Discontinued Reference number: GID-TA10203
Discontinued Reference number: GID-TA10234
Discontinued Reference number: GID-TA10707
Discontinued Reference number: GID-TA10841
Discontinued Reference number: GID-TAG479
Evidence-based recommendations on encorafenib (Braftovi) with binimetinib (Mektovi) for treating unresectable or metastatic BRAF V600 mutation-positive melanoma in adults.
Evidence-based recommendations on nivolumab (Opdivo) with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma in adults.
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults.